Clorox CLX FAIRLY VALUED Buying Index™ 3 Value Rating

Valuentum Retail Equity Research Ratings as of 19-Jun-2021 Data as of 18-Jun-2021

Buying Index™ 3 Value RatingEconomic CastleVery Attractive

Investment ConsiderationsDCF ValuationRelative Valuation

Stock Chart (weekly) ValueCreation™ValueRisk™ValueTrend™Cash Flow GenerationFinancial LeverageGrowthTechnical EvaluationRelative StrengthMoney Flow Index (MFI)Upside/Downside Volume (U/D)Near-term Technical Resistance, 10-wk MADCF = Discounted Cash Flow; MFI, U/D = Please see glossary. MA = Moving Average

Business Quality ValueCreation™

ValueRisk™ Very Poor Poor Good ExcellentCompany Vitals Investment HighlightsMarket Cap (USD) $22,085Avg Weekly Vol (30 wks) 7,23030-week Range (USD) 172.35 - 231.11Valuentum Sector Consumer Staples5-week Return -3.0%13-week Return -9.1%30-week Return -14.5%Dividend Yield % 2.7% Firms that generate economic profits with little operating variability score near the top right of the matrix.

Dividends per Share 4.64 Relative Valuation Forward P/E PEG Price / FV

Forward Dividend Payout Ratio 60.3% Coca-Cola 24.8 3.1 133.0%Est. Normal Diluted EPS 8.98 Philip Morris 15.9 2.0 98.4%P/E on Est. Normal Diluted EPS 19.3 Procter & Gamble 23.9 2.9 130.8%Est. Normal EBITDA 1,740 Wal-Mart 25.8 1.9 124.1%Forward EV/EBITDA 15.7 Peer Median 24.3 2.4 127.4%EV/Est. Normal EBITDA 13.8 Clorox 22.5 2.9 85.6%Forward Revenue Growth (5-yr) 4.4% Price / FV = Current Stock Price divided by Estimated Fair Value

Forward EPS Growth (5-yr) 8.1% Financial Summary ProjectedNMF = Not Meaningful; Est. = Estimated; FY = Fiscal Year

Fiscal Year End: Jun-19 Jun-20 Jun-21

Returns Summary 3-year Historical Average Revenue 6,214 6,721 7,467Return on Equity 128.5% Revenue, YoY% 1.5% 8.2% 11.1%Return on Assets 16.6% Operating Income 1,124 1,274 1,327ROIC, with goodwill 31.9% Operating Margin % 18.1% 19.0% 17.8%ROIC, without goodwill 56.8% Net Income 820 939 983ROIC = Return on Invested Capital; NMF = Not Meaningful Net Income Margin % 13.2% 14.0% 13.2%Leverage, Coverage, and Liquidity Diluted EPS 6.32 7.36 7.70In Millions of USD Diluted EPS, YoY % 1.0% 16.4% 4.6%Total Debt 2,780 Free Cash Flow (CFO-capex) 786 1,292 1,032Net Debt 1,909 Free Cash Flow Margin % 12.6% 19.2% 13.8%Total Debt/EBITDA 1.9 In Millions of USD (except for per share items)

Net Debt/EBITDA 1.3 LARGE-CEBITDA/Interest 14.7 GOODCurrent Ratio 1.4Quick Ratio 1.1

Industry $202.00 $162.00 - $242.00 LARGE-CAP VALUE Consumer Staples Recession Resistant

Visit us at www.valuentum.com

Clorox CLX FAIRLY VALUED Estimated Fair Value Fair Value Range Investment Style Sector

EXCELLENTLOW

POSITIVESTRONGMEDIUMMODEST

Clorox recently raised its annual long-term organic sales growth forecast, though the firm faces significant near-term headwinds due to cost inflation pressures and logistical hurdles.

FAIRLY VALUEDNEUTRAL

BEARISHWEAK

NEUTRALBEARISH

179.00

The week with the highest trading volume out of the last 30 weeks was a week of heavy selling, or distribution (red bar).

• Clorox, like many other big brand companies,realized the importance of the shift to e-commerce anddigital marketing several years ago. It continues toinvest heavily in its digital operations, and its e-commerce sales have grown at a brisk CAGR sincefiscal 2015.

• Clorox has noteworthy long-term annual financialgoals: organic sales growth of 3%-5%, EBIT marginimprovement of 25-50 basis points, and free cash flowof 11%-13% of sales. The company views itsinternational growth runway quite favorably. Cloroxacquired a majority stake in its longstanding SaudiArabia joint venture in July 2020 for ~$0.1 billion.

----- Actual -----

• Clorox continues to innovate by launching newproducts, entering new markets, and improving itspackaging processes to eliminate waste and reducecosts. The firm is placing a great emphasis on itsdigital marketing strategies and its e-commerceoperations continue to impress.

Medium

High

Low 1• Clorox’s brands include its namesake bleach andcleaning products, Pine-Sol cleaners, Fresh Step catlitter, Glad bags, Kingsford charcoal, and Burt's Beespersonal care products. ~80% of its revenue isgenerated by brands that hold the #1 or #2 marketshare positions in their categories. Clorox was foundedin 1913 and is headquartered in Oakland, California. Very High

• Clorox is a Dividend Aristocrat that has raised itsannual dividend each year since 1977. Over 80% of itsnet sales come from the US. The firm is facing costinflation headwinds in the near-term and is turning toprice increases to offset those hurdles.

NMF = Not Meaningful

The information and data contained in this report is not represented or warranted to be timely, complete, accurate, or correct. This report is for informational purposes only and should not be considered a solicitation to buy or sell a security. Before acting on any information in this report, you should consider whether the information is suitable for your particular circumstances and, if necessary, seek professional advice. Assumptions, opinions, and estimates are based on our judgment as of the date of the report and are subject to change without notice. Valuentum is not responsible for any errors or omissions or for results obtained from the use of this report. Redistribution is prohibited without written permission. To license Valuentum research, contact us at [email protected].

Structure of the Household Products IndustryFirms in the household products industry sell some of the most recognized branded consumer packaged goods in the world and often hold a significant market share position in a variety of product categories. Though the industry is characterized by stiff competition from retailers’ private-label brands, constituents tend to boast meaningful competitive advantages due to their brand strength/reputation and generate high returns on invested capital. Household products companies remain tied to the vicissitudes of consumer spending, but we tend to like the structure of the group.

146.00

156.00

166.00

176.00

186.00

196.00

206.00

216.00

226.00

236.00

0

10,000,000

20,000,000

30,000,000

40,000,000

50,000,000

60,000,000

70,000,000

Valuentum Retail Equity Research (10=best) Data as of 18-Jun-2021


Economic Profit Analysis

ValueCreation™ EXCELLENT Return on Invested Capital (ROIC)

ROIC - WACC Spread, 3-year historical average 48.4%ROIC - WACC Spread, 5-year projected average 69.1%These spreads equal the firm's annual average ROIC (excluding goodwill) less its WACC.

ValueTrend™ POSITIVE

Weighted Average Cost of Capital (WACC) The graph above shows the firm's ROIC (excluding goodwill) compared with historical averages and its WACC.

ROIC CalculationFiscal Year End: Jun-18 Jun-19 Jun-20

Earnings before InterestOperating Income after Depreciation 1,136 1,124 1,274- Adjusted Taxes (at 20% of EBIT) 227 225 255+ Amortization 0 0 0+ Non-cash Operating Items 96 -8 427- Minority Interest 0 0 0Earnings before Interest 1,005 891 1,446

Cost of Equity Invested CapitalRisk Free Rate Assumption Inventories 506 512 454Fundamental Beta (ERP multiplier) + Receivables 600 631 648Estimated Equity Risk Premium + Current Deferred Income Taxes 0 0 0Cost of Equity Assumption + Other Current Assets 74 51 47

+ Property, Plant and Equipment, Net 996 1,034 1,103After-tax Cost of Debt + Goodwill, Net (Cost in Excess) 1,602 1,591 1,577Risk Free Rate Assumption + Intangibles 929 912 894Synthetic Credit Spread + Non Current Deferred Income Taxes 0 0 0Cost of Debt Assumption - Accounts Payable 507 1,044 1,354Cash Tax Rate Assumption - Other Current Liabilities 494 0 64After-tax Cost of Debt Assumption

Invested Capital, with goodwill 3,706 3,687 3,305Cost of Preferred Stock Invested Capital, without goodwill 2,104 2,096 1,728Preferred DividendsValue of Preferred Stock Return on Invested Capital, with goodwill 30.2% 24.1% 41.4%Cost of Preferred Assumption Return on Invested Capital, without goodwill 52.2% 42.4% 75.6%

In Millions of USD

Weighted Average Cost of Capital (WACC)ERP = Equity Risk Premium

Clorox CLX FAIRLY VALUED Estimated Fair Value Fair Value Range Investment Style Sector Industry

Clorox receives a ValueTrend™ rating of POSITIVE, which is based on the company'strailing three-year performance. The firm's ROIC (excluding goodwill) increased to75.6% last year from its trailing 3-year average of 56.8%. We expect ROIC (excludinggoodwill) to be in the ballpark of about 86% by the end of our discrete forecast period,with upside potential to about 104% over that time period.

---------- Actual ----------

4.3%

$202.00 $162.00 - $242.00 LARGE-CAP VALUE Consumer Staples Recession Resistant

The best measure of a firm's ability to create value for shareholders is expressed bycomparing its return on invested capital (ROIC) with its weighted average cost ofcapital (WACC). The gap or difference between ROIC and WACC is called the firm'seconomic profit spread. Clorox's 3-year historical return on invested capital (withoutgoodwill) is 56.8%, which is above the estimate of its cost of capital of 8.4%. As such,we assign the firm a ValueCreation™ rating of EXCELLENT. In the chart to the right,we show the probable path of ROIC in the years ahead based on the estimated volatilityof key drivers behind the measure. The solid grey line reflects the most likely outcome,in our opinion, and represents the scenario that results in our fair value estimate.

20.0%4.4%

00

NA

8.4%

0.76.5%8.9%

4.3%1.22%

5.5%


Note: Valuentum may provide an adjusted ROIC measure to better reflect the economic substance of a company's operations, as in the case of companies with negative invested capital.

104.5%

86.1%

52.2%

42.4%

75.6%

67.7%

WACC, 8.4%

0.0%

20.0%

40.0%

60.0%

80.0%

100.0%

120.0%

88.8%

11.2%Equity

Debt

Preferred

Capital Structure



Growth Analysis

Revenue Growth MODEST Projected Revenue (in millions of USD) Source: Company Filings, Valuentum Projections

Last Fiscal Year

Revenue3-year Historical

CAGR5-year Projected

CAGRClorox USD 6,721 4.0% 4.4%

Coca-Cola USD 33,014 -2.3% 6.7%

Philip Morris USD 28,694 -0.1% 5.3%

Procter & Gamble USD 70,950 2.9% 4.8%

Wal-Mart USD 559,151 3.8% 2.0%

Peer Median 1.4% 5.0%

Industry Median 2.4% 4.4%

In the chart above, we show our baseline forecast for revenue as well as potential upside and downside cases.

EBITDA Growth Projected EBITDA (in millions of USD) Source: Company Filings, Valuentum Projections

Last Fiscal Year

EBITDA3-year Historical

CAGR5-year Projected

CAGRClorox USD 1,454 4.1% 7.2%

Coca-Cola USD 11,386 9.1% 9.7%

Philip Morris USD 12,649 0.7% 7.2%


Wal-Mart USD 33,700 2.9% 8.0%



In the chart above, we show our baseline forecast for EBITDA as well as potential upside and downside cases.

Net Income Growth Projected Net Income (in millions of USD) Source: Company Filings, Valuentum Projections

Last Fiscal Year Net Income

3-year Historical CAGR

5-year Projected CAGR

Clorox USD 939 10.2% 8.1%

Coca-Cola USD 7,747 83.8% 8.6%



Wal-Mart USD 13,510 11.1% 14.8%



In the chart above, we show our baseline forecast for net income as well as potential upside and downside cases.


Clorox's revenue expansion has been greater than the median of both its peer group andindustry group during the past three years. We expect the firm's pace of revenue growthto fall below the median of both its peer group and industry group during the next fiveyears. Our growth assessment of each firm is based on the firm's 5-year forwardrevenue CAGR. Clorox's future pace of revenue growth is MODEST, in our opinion.


Clorox's EBITDA expansion has been greater than that of both its peer group andindustry group during the past three years. We expect the firm's pace of EBITDAgrowth to fall below that of both its peer group and industry group during the next fiveyears. Coca-Cola sports the highest expected EBITDA growth rate among peers.

Clorox's net income expansion has trailed that of its peer group but has been greaterthan that of its industry group during the past three years. We expect the firm's pace ofnet income growth to fall below that of both its peer group and industry group duringthe next five years. Wal-Mart sports the highest net income growth rate among peers.


6,124 6,2146,721

8,835

8,3327,830

0

1,000

2,000

3,000

4,000

5,000

6,000

7,000

8,000

9,000

10,000

1,302 1,3041,454

2,194

2,0561,919

0

500

1,000

1,500

2,000

2,500

823 820939

1,567

1,387

1,208

0

200

400

600

800

1,000

1,200

1,400

1,600

1,800



Cash Flow and Financial Leverage AnalysisCash Flow Generation STRONG Financial Leverage MEDIUM

The bars above show the firms operating cash flow, capital expenditures, and free cash flow, respectively. The bars above show the firm's annual debt-to-EBITDA. The red line shows the firm's normalized measure.

Cash Flow from Operations Projected Operating Cash Flow (in millions of USD) Source: Company Filings, Valuentum Projections

Last Fiscal Year CFO


5-year Projected CAGR

Clorox USD 1,546 21.2% 4.9%

Coca-Cola USD 9,844 12.1% 8.6%



Wal-Mart USD 36,074 8.4% 1.8%



In the chart above, we show our baseline forecast for CFO as well as potential upside and downside cases.

Free Cash Flow (CFO-capital expenditures) Projected Free Cash Flow (in millions of USD) Source: Company Filings, Valuentum Projections

Last Fiscal Year FCF


5-year Projected CAGR Source: Company Filings, Valuentum Projections

Clorox USD 1,292 26.6% 5.5%

Coca-Cola USD 8,667 17.7% 8.0%



Wal-Mart USD 25,810 12.2% -2.9%



In the chart above, we show our baseline forecast for free cash flow as well as potential upside and downside cases.


Firms that generate a free cash flow margin (free cash flow divided by total revenue)above 5% are usually considered cash cows. Clorox's free cash flow margin hasaveraged about 14.9% during the past 3 years. As such, we think the firm's cash flowgeneration is relatively STRONG. The free cash flow measure shown above is derivedby taking cash flow from operations less capital expenditures and differs fromenterprise free cash flow (FCFF), which we use in deriving our fair value estimate forthe company. For more information on the differences between these two measures,please visit our website at Valuentum.com. At Clorox, cash flow from operationsincreased about 59% from levels registered two years ago, while capital expendituresexpanded about 31% over the same time period.

Firms that exhibit high leverage tend to be more risky than firms with relatively lowdebt loads, all else equal. We measure financial leverage by taking a firm's currenttotal debt load and dividing it by the firm's trailing average 3-year annual EBITDA.Firms that are over 3 for this metric, we rate as having high leverage. Companies thathave less than 1.5 turns of leverage (or a measure below 1.5), we rate as having lowleverage. Clorox's normalized debt-to-EBITDA measure of about 2.05 puts it in theMEDIUM camp.


Clorox's cash flow from operations expansion has been greater than that of both its peergroup and industry group during the past three years. We expect the firm's pace of cashflow from operations growth to fall below that of both its peer group and industry groupduring the next five years. Coca-Cola sports the highest expected cash flow fromoperations growth rate among peers.

Clorox's free cash flow expansion has been greater than that of both its peer group andindustry group during the past three years. We expect the firm's pace of free cash flowgrowth to fall below that of both its peer group and industry group during the next fiveyears. Coca-Cola sports the highest expected free cash flow growth rate among peers.


974 992

1,546

194 206 254

780 786

1,292

Jun-18 Jun-19 Jun-20

Cash from Operations Capital Expenditures Free Cash Flow

Clorox - normalized leverage, 2.05

0

0.5

1

1.5

2

2.5

3

3.5

6/30/2018 6/30/2019 6/30/2020

Clorox- annual leverage Clorox - normalized leverageMedium Threshold HighThreshold

974 992

1,546

2,451

1,966

1,480

0

500

1,000

1,500

2,000

2,500

3,000

780 786

1,292

2,155

1,687

1,218

0

500

1,000

1,500

2,000

2,500



Valuation Analysis

Valuation Assumptions Valuation BreakdownIn Millions of USD (except for per share items)

Revenue CAGR %Avg. EBIT Margin %Avg. Cash Tax Rate %Earnings Before Interest CAGR %Earnings Per Share CAGR %Free Cash Flow to the Firm CAGR %Earnings before interest = Net operating profits less adjusted taxes

Phase II --> III FCFF CAGR % 2.8% (II) 3% (III)Cost of Equity %After-tax Cost of Debt %Discount Rate (WACC) %Synthetic credit spread = 1.217%

Phase I Present ValuePhase II Present ValuePhase III Present ValueTotal Firm Value

Net Balance Sheet Impact

Total Equity ValueDiluted Shares OutstandingFair Value per Share

DCF Valuation Summary Enterprise Free Cash FlowFiscal Year End: 6/30/2018 6/30/2019 6/30/2020

1,005 891 1,446166 180 180194 206 254110 -255 -351

- Acquisitions 681 0 0186 1,120 1,723

In Millions of USD

Source: Company Filings, Valuentum Projections

Company NameValuentum Buying

Index™Forward Price-to-

Earnings

Price/Earnings-to-Growth (PEG), 5-

yearEV/Est. Normal

EBITDA

5-year Forward Earnings per Share CAGR

3-year Hist Avg ROIC, without

goodwillDividend Yield

%

Stock Price / Fair Value Estimate

Clorox 3 22.5 2.9 13.8 8.1% 56.8% 2.7% 85.6%

Coca-Cola 4 24.8 3.1 16.1 9.7% 41.8% 3.1% 133.0%

Philip Morris 5 15.9 2.0 10.7 9.4% 90.6% 4.9% 98.4%

Procter & Gamble 4 23.9 2.9 15.2 9.6% 32.5% 2.5% 130.8%

Wal-Mart 4 25.8 1.9 10.7 16.0% 26.3% 1.6% 124.1%

Peer Median 4.0 24.3 2.4 13.0 9.7% 37.2% 2.8% 127.4%

Industry Median 4.0 23.3 2.5 11.3 9.6% 24.0% 2.3% 104.1%



5-year Projections In the chart below, we show the build up to our estimate of total enterprise value forClorox and the break down to the firm's total equity value, which we estimate to beabout 25.8USD billion. The present value of the enterprise free cash flows generatedduring each phase of our model and the net balance sheet impact is displayed. Wedivide total equity value by diluted shares outstanding to arrive at our $202 per sharefair value estimate.

4.4%19.6%20.0%

8.4%Results5,565

5.2%8.1%0.5%

Long-term Projections

8.9%4.4%

-1,909

25,801127.7

$202.00

11,93410,21127,710

Company Metrics versus Peer and Industry Medians

P/E on Est. Normal Diluted EPS Forward EV/EBITDA

19.3 15.7

In Millions of USD

---------- Actual ----------

We think Clorox is worth $202 per share with a fair value range of $162.00 -$242.00. The margin of safety around our fair value estimate is driven by the firm'sLOW ValueRisk™ rating, which is derived from an evaluation of the historicalvolatility of key valuation drivers and a future assessment of them. Our near-termoperating forecasts, including revenue and earnings, do not differ much from consensusestimates or management guidance. Our model reflects a compound annual revenuegrowth rate of 4.4% during the next five years, a pace that is higher than the firm's 3-year historical compound annual growth rate of 4%. Our model reflects a 5-yearprojected average operating margin of 19.6%, which is above Clorox's trailing 3-yearaverage. Beyond year 5, we assume free cash flow will grow at an annual rate of 2.8%for the next 15 years and 3% in perpetuity. For Clorox, we use a 8.4% weighted averagecost of capital to discount future free cash flows.

Earnings before Interest+ Depreciation - Capital Expenditures - Change in Working Capital

Enterprise Free Cash Flow (FCFF)

Our future forecasts for key valuation drivers result in a future free enterprise cashflow stream. Above, we show how we calculate enterprise free cash flow and thehistorical performance of the metric for Clorox. Over the next five years, we expectthe firm's enterprise free cash flow to expand at about a 0% compound annual growthrate. During years 6 through 20, we expect the measure to grow at a 2.8% rate.Beyond year 20 (in perpetuity), we grow the firm's free cash flow at inflation (3%).

19.0 13.0

19.7 14.9

17.6 12.8

21.5 18.0

13.6 12.1

20.4 16.9

View back of report for a full list of industry constituents covered by Valuentum. VBI: Valuentum's ranking for the attractiveness of this investment at the date of the report.


5,565

11,934

10,211

1,909

25,801

0

5,000

10,000

15,000

20,000

25,000

30,000

Yr 1-5 Yr 6-20 Perpetuity Net Balance SheetImpact

Equity Value



Margin of Safety Analysis

Range of Potential Outcomes ValueRisk™ LOW

Revenue Volatility 4.8%Gross Margin Volatility 6.1%Earnings (EBI) Volatility 17.1%Cash Flow (FCFF) Volatility 36.8%Fair Value Range 20.0%The Fair Value Range sets the premium or discount on our estimate of the firm's fair value.

Upside and Downside ProbabilitiesProbability (fair value < $0) Less than 0.1%Probability (fair value > 2x current share price) 0.02%

Future Path of Fair Value

The graph above shows the expected future fair value of the firm's shares relative to its current stock price.


Our discounted cash flow process values each firm on the basis of the present value ofall future free cash flows. Although we estimate the firm's fair value at about $202 pershare, every company has a range of probable fair values that's created by theuncertainty of key valuation drivers (like future revenue or earnings, for example). After all, if the future were known with certainty, we wouldn't see much volatility in themarkets as stocks would trade precisely at their known fair values. Our ValueRisk™rating sets the margin of safety or the fair value range we assign to each stock. In thegraph above, we show this probable range of fair values for Clorox. We think the firmis attractive below $162 per share (the green line), but quite expensive above $242 pershare (the red line). The prices that fall along the yellow line, which includes our fairvalue estimate, represent a reasonable valuation for the firm, in our opinion.

We strive to answer a few questions that investors often ask: 1) What are the chancesof a total loss of investment in this company? and 2) What is the chance that thecompany is really worth twice what I paid for it? The probability (fair value < 0)strives to answer the first question. It indicates the chance that the firm mayencounter insolvency based on the characteristics of its cash flow stream, capitalstructure, and risk profile. The probability (fair value > 2x current share price) strivesto answer the second question. It is our best estimate of whether investors areparticipating in a half-off sale by buying the company's shares at current prices.

We estimate Clorox's fair value at this point in time to be about $202 per share. As timepasses, however, companies generate cash flow and pay out cash to shareholders in theform of dividends. The chart to the right compares the firm's current share price withthe path of Clorox's expected equity value per share over the next three years, assumingour long-term projections prove accurate. The range between the resulting downsidefair value and upside fair value in Year 3 represents our best estimate of the value of thefirm's shares three years hence. This range of potential outcomes is also subject tochange over time, should our views on the firm's future cash flow potential change. Theexpected fair value of $242 per share in Year 3 represents our existing fair value pershare of $202 increased at an annual rate of the firm's cost of equity less its dividendyield. The upside and downside ranges are derived in the same way, but from the upperand lower bounds of our fair value estimate range.



Clorox receives a ValueRisk™ rating of LOW based of the historical volatility of keydrivers of economic value creation. The fair value range sets the margin of safetyaround our fair value estimate of the firm's shares.

$162

$202

$242

0 50 100 150 200 250 300 350 400

$290

$242Current Share Price, $173

$194

$0

$50

$100

$150

$200

$250

$300

$350

Current Share Price Yr 1 Fair Value Yr 2 Fair Value Yr 3 Fair Value



Technical Analysis

Technical Evaluation BEARISH Money Flow Index (MFI) NEUTRAL

30-week Price and Volume Chart (weekly)Relative Price Strength WEAK

5-week Company Performance -3.0%5-week Market Benchmark Performance 3.4%5-week Relative Performance vs. Market Benchmark -6.4%13-week Company Performance -9.1%13-week Market Benchmark Performance 7.2%13-week Relative Performance vs. Market Benchmark -16.3%30-week Company Performance -14.5%30-week Market Benchmark Performance 19.4%30-week Relative Performance vs. Market Benchmark -33.9%

Upside/Downside Volume BEARISH Timeliness Matrix™ Equity Valuation

Relative Strength

Firms that are undervalued and currently showing near-term pricing strength score near the top right of the matrix.

Clorox CLX FAIRLY VALUED

The firm's near-term moving average (5-week, grey line) and medium-term movingaverage (13-week, red line) are shown in the chart above. Typically, when a shorter-term moving average crosses a medium- or longer-term moving average from below, itrepresents a bullish signal. If the short-term moving average crosses from above, tradersoften view this as bearish. Clorox's 5-week moving average is below its 13-weekmeasure, indicating a BEARISH trend. This activity further confirms the company's 30-week downtrend.

The Money Flow Index (MFI) is an oscillator that uses price and volume to measurebuying and selling pressure. Chartists often look for overbought (above 80) andoversold (below 20) levels to warn of unsustainable near-term price extremes.Clorox's MFI of 33 (green line) is neutral, suggesting the firm's stock is neitheroverbought nor oversold at this time. However, a score below 50 tends to favor bears.The MFI can also be used to gauge the strength or weakness of a firm's price trend. InClorox's case, its stock price and money flow neither reveals a bullish nor bearishdivergence, further supporting our neutral view on its money flow action.

A firm's relative price strength can be assessed over any number of time horizons. Weshow the firm's performance over the past 5 weeks, 13 weeks, and 30 weeks below.In arriving at our relative strength rating for each company, we assess the past 13weeks, which includes the market's reaction to the firm's most recently reportedquarter, where applicable, and other more recent economic events. During the past 13weeks, Clorox's shares returned -9.1%, while the market benchmark returned 7.2%.We think Clorox's 13-week relative price performance is WEAK.

In the chart above, we pinpoint the heaviest accumulation or distribution week of thefirm, determined by the week with the highest trading volume during the past 30 weeks.A heavy accumulation (buying) or distribution (selling) week often determines thefuture near-term direction of the firm's share price, as money managers continue tomove in or out of the stock in the days and weeks ahead driving the stock up or down,respectively. For Clorox, the week with the highest trading volume out of the last 30weeks was a week of heavy buying, or accumulation (green bar). Such market activitycould indicate a reversal of a downtrend or further confirmation of the firm's uptrend.

Overvalued Fairly Valued Undervalued

Estimated Fair Value Fair Value Range Investment Style Sector Industry $202.00 $162.00 - $242.00 LARGE-CAP VALUE Consumer Staples Recession Resistant

Weak 1Companies that are undervalued and showing near-term relative price strength couldrepresent timely buys, as the stock may be attractive to both value and momentuminvestors. A cross section of the firm's equity valuation and its relative share pricestrength is shown in the matrix above. We tend to prefer undervalued stocks that have strong pricing momentum, also called Valuentum stocks.

The level and trend of the Upside/Downside (U/D) volume ratio reveals whetherinstitutional participation has been bullish or bearish as of late. Clorox's U/D volumeratio of 0.5 is not only less than 1 but also is lower than its trailing average, indicatingBEARISH institutional interest during the past several weeks.

Strong

Neutral


146156166176186196206216226236

0

10,000,000

20,000,000

30,000,000

40,000,000

50,000,000

60,000,000

70,000,000

5-week Moving Average 13-week Moving

Average

Stock Price

158

168

178

188

198

208 Overbought Line

Oversold Line

4033

0102030405060708090

1.3

0.5

Average, 0.9

0.0

0.2

0.4

0.6

0.8

1.0

1.2

1.4

- 10-week Moving Average



Pro Forma Income Statement -------------------- Historical --------------------

In Millions of USD (except for per share items)Jun-18 Jun-20

Total Revenue 6,124 6,721

Cost of Goods Sold 3,449 3,658

Selling, General and Administrative Expenses 837 969

Other Operating Expenses 702 820

Operating Income 1,136 1,274

Unusual items 0 0

Operating Income, including unusual items 1,136 1,274

Interest Expense (85) (99)

Other Non-operating Income 3 10

Pre-tax Income 1,054 1,185

Income Taxes 231 246

Income after tax 823 939

Minority Interest and Equity Income 0 0

Net Income, excluding extra items 823 939

Income Available to Common, excluding extra items 823 939

Diluted Earnings per Share, excluding extra items 6.25 7.36

Diluted Weighted Shares Outstanding 131.6 127.7

Source: Company Filings, Xignite, Valuentum Projections


---------- Projected ----------


6,214 7,467 7,407


748 924 913

3,486 4,123 4,072

856 1,092 1,079

0 0 0

1,124 1,327 1,343

1,124 1,327 1,343

(3) 0 0

(97) (99) (99)

204 246 249

1,024 1,228 1,244

0 0 0

820 983 995

820 983 995

820 983 995

129.8 127.7 127.7


6.32 7.70 7.80

Note: Pro forma data in discounted cash-flow valuation may reflect significant adjustments from GAAP accounting data, including cash (not effective) tax rates and other analytical adjustments on a backward-looking and forward-looking basis. No individual data, by itself, found in this report should be used to make any investment decision.



Pro Forma Balance Sheet -------------------- Historical --------------------


AssetsTotal Cash (including marketable securities) 131 871Inventory 506 454Accounts Receivable 600 648Other Current Assets 74 47Total Current Assets 1,311 2,020

Gross Fixed Assets 3,057 3,327(Accumulated Depreciation) (2,061) (2,224)Net Property, Plant, and Equipment 996 1,103

Goodwill, Net 1,602 1,577Intangibles, Net 929 894Other Long-term Assets 222 619Total Assets 5,060 6,213

LiabilitiesAccounts Payable 507 1,354Other Current Liabilities 494 64Current Portion of Long-term Debt 199 0Total Current Liabilities 1,200 1,418

Long-term Debt 2,284 2,780Other Long-term Liabilities 850 1,107Total Liabilities 4,334 5,305

Preferred Stock 0 0

Shareholders' EquityCommon Stock and Additional Paid in Capital 1,134 1,296Retained Earnings 2,797 3,567Other Equity (3,205) (3,955)Total Shareholders' Equity 726 908

Total Liabilities and Shareholders' Equity 5,060 6,213

Clorox CLX FAIRLY VALUED

---------- Projected ----------


Estimated Fair Value Fair Value Range Investment Style Sector Industry $202.00 $162.00 - $242.00 LARGE-CAP VALUE Consumer Staples Recession Resistant

512 518 518631 721 716

111 1,310 1,821

3,184 3,589 3,855(2,150) (2,424) (2,622)

51 47 471,305 2,596 3,102

912 894 894274 619 619

1,034 1,165 1,233

1,591 1,577 1,577

1,044 1,496 1,403

5,116 6,851 7,425

1,440 1,540 1,491

0 44 88396 0 0

4,557 5,427 5,378

2,287 2,780 2,780830 1,107 1,107

1,205 1,296 1,2963,150 3,957 4,331

0 0 0

5,116 6,851 7,425

(3,796) (3,830) (3,580)559 1,423 2,047






Pro Forma Cash Flow Statement -------------------- Historical --------------------


Cash from OperationsNet Income 823 939Depreciation and Amortization 166 180Deferred Income Taxes (23) 0Operating Gains Or Losses 96 427Changes in Working Capital (88) 0

Cash Flow from Operations 974 1,546

Cash from InvestingPurchase of Property, Plant, Equipment (194) (254)Other Investing Cash Flows (665) 2Cash Flow from Investing (859) (252)

Cash from FinancingIssuance (Retirement) of Stock (226) (86)Issuance (Retirement) of Debt 277 96Dividends Paid (450) (533)Other Financing Cash Flows 0 0Cash Flow from Financing (399) (523)

Foreign Exchange (3) (5)

Net Change in Cash (287) 766




---------- Projected ----------

180 200 1980 0 0

820 983 995

992 1,293 1,400

(8) 125 2500 (14) (44)

(196) (262) (267)

(206) (262) (267)10 0 0

(490) (592) (622)0 0 0

(514) 0 0189 0 0

(2) 0 0

(21) 439 511

(815) (592) (622)






Recession ResistantRecession Resistant FAIRLY VALUED

Company Name TickerMarket Cap (USD-

mil) DCF Valuation ValueCreation™ ValueRisk™ ValueTrend™ Technicals Relative Strength

Altria Group MO 86,090 FAIRLY VALUED EXCELLENT LOW POSITIVE BEARISH WEAK

Anheuser-Busch InBev BUD 152,755 FAIRLY VALUED EXCELLENT MEDIUM NEGATIVE BULLISH STRONG

Archer-Daniels-Midland ADM 34,152 FAIRLY VALUED GOOD MEDIUM NEGATIVE VERY BEARISH NEUTRAL

Campbell Soup CPB 13,672 FAIRLY VALUED EXCELLENT MEDIUM NEGATIVE BEARISH WEAK

Casey's General CASY 7,328 FAIRLY VALUED GOOD MEDIUM NEGATIVE BEARISH WEAK

Church & Dwight CHD 21,104 FAIRLY VALUED EXCELLENT LOW POSITIVE BEARISH WEAK

Clorox CLX 22,085 FAIRLY VALUED EXCELLENT LOW POSITIVE BEARISH WEAK

Coca-Cola KO 235,647 OVERVALUED EXCELLENT MEDIUM NEGATIVE BULLISH NEUTRAL

Colgate-Palmolive CL 69,620 OVERVALUED EXCELLENT LOW POSITIVE VERY BEARISH WEAK

Costco COST 169,073 FAIRLY VALUED EXCELLENT LOW POSITIVE BULLISH NEUTRAL

Fresh Del Monte FDP 1,544 FAIRLY VALUED POOR LOW NEGATIVE BULLISH STRONG

General Mills GIS 36,651 FAIRLY VALUED EXCELLENT LOW POSITIVE VERY BEARISH WEAK

Hormel Foods HRL 26,039 FAIRLY VALUED EXCELLENT LOW NEGATIVE VERY BEARISH WEAK

Kellogg K 21,939 FAIRLY VALUED EXCELLENT LOW POSITIVE VERY BEARISH WEAK

Keurig Dr Pepper KDP 41,686 FAIRLY VALUED EXCELLENT LOW NEGATIVE VERY BULLISH WEAK

Kimberly-Clark KMB 44,076 FAIRLY VALUED EXCELLENT LOW POSITIVE BEARISH WEAK

Kraft Heinz KHC 49,734 FAIRLY VALUED EXCELLENT MEDIUM NEGATIVE VERY BEARISH WEAK

Kroger KR 30,264 FAIRLY VALUED GOOD MEDIUM POSITIVE BULLISH WEAK

Lancaster Colony LANC 5,258 FAIRLY VALUED EXCELLENT MEDIUM NEGATIVE BULLISH NEUTRAL

McCormick MKC 23,178 FAIRLY VALUED EXCELLENT MEDIUM POSITIVE BEARISH WEAK

Molson Coors TAP 11,757 FAIRLY VALUED GOOD LOW POSITIVE VERY BEARISH NEUTRAL

Mondelez Intl MDLZ 89,544 FAIRLY VALUED GOOD LOW POSITIVE BULLISH NEUTRAL

PepsiCo PEP 197,761 FAIRLY VALUED EXCELLENT LOW POSITIVE BULLISH WEAK

Philip Morris PM 151,765 FAIRLY VALUED EXCELLENT LOW POSITIVE NEUTRAL STRONG

Procter & Gamble PG 360,588 OVERVALUED EXCELLENT LOW POSITIVE BULLISH NEUTRAL

Smucker SJM 14,854 FAIRLY VALUED EXCELLENT LOW NEGATIVE VERY BEARISH WEAK

Sysco SYY 38,402 FAIRLY VALUED EXCELLENT MEDIUM NEGATIVE BEARISH WEAK

Target TGT 108,514 FAIRLY VALUED EXCELLENT LOW POSITIVE BULLISH STRONG

Tyson Foods TSN 26,557 FAIRLY VALUED EXCELLENT MEDIUM POSITIVE BEARISH WEAK

Wal-Mart WMT 399,149 OVERVALUED EXCELLENT LOW POSITIVE BULLISH WEAK


We think the Recession Resistant industry is fairly valued at this time. The industry'smarket cap is trading between 80% and 120% of our estimate of its fair value based onour DCF process. Although we use a firm-specific ValueRisk™ measure to determinewhether a firm is undervalued or overvalued based on our DCF process, we consider anindustry to be undervalued if it is trading below 80% of our estimate of its fair valueand overvalued if it is trading at over 120% of our estimate of its fair value. We thinkthese fair value ranges are appropriate given the diversification benefits of holding abasket of stocks. Although there may be individual opportunities within the RecessionResistant industry, we don't find the industry as a whole attractive based solely onvaluation.


LARGE-CAP CORE NEUTRAL

LARGE-CAP CORE ATTRACTIVE


The above bar chart reveals the price/fair value of the company, its peers, and the industry as a whole.Shaded blue denotes that the firm has earned the highest rating for that respective category.Investment Style Relative Valuation


MEGA-CAP CORE NEUTRAL

LARGE-CAP CORE UNATTRACTIVE


MID-CAP CORE ATTRACTIVE


LARGE-CAP VALUE NEUTRAL




SMALL-CAP CORE ATTRACTIVE








MID-CAP CORE UNATTRACTIVE


LARGE-CAP VALUE UNATTRACTIVE



LARGE-CAP VALUE ATTRACTIVE





85.6%

127.4%

104.1%

0%

20%

40%

60%

80%

100%

120%

140%

Clorox Peer Median Recession Resistant

Valuentum's Full Page Stock Report


BA

G

I

N

C

J

D

M

H

E

L

K

A DCF ValuationShows whether the firm is undervalued, fairly valued, or overvalued based on our DCF process and by how much.

B Valuentum Buying Index (VBI)Provides insight into the timeliness of an investment opportunity. We rank firms from 1 to 10 based on rigorous fiancial, valuation, and technical analysis. A 10 represents one of our top picks.

C Valuentum Value Rating (VVR) Indicates whether we think a firm is undervalued, fairly valued, or overvalued on the basis of our DCF process.

D Investment ConsiderationsEvaluates firms on 12 different measures, from the firm's growth and cash flow generation to the stock's money flow index and upside/downside volume. We reveal technical support and resistance levels.

E 30-week Price and Volume ActionDisplays the last accumulation or distribution week of the stock and historical price and volume action.

G Company VitalsShows sector,industry and other relevant company information.

H Business QualitySummary of the firm's ability to create value for shareholders compared wth the underlying risk of its operations.

I Normalized EPS and EBITDAEstimation of the firm's normalized earnings measures and the corresponding valuation mutliples.

J Investment HighlightsOur opinion of the company, including analysis of its financial and technical strengths and weaknesses.

K Relative ValuationComparison of the firm's PE, PEG, and Price/FV ratios versus peers.

L Returns Summary3-year averages of the firm's key return measures, including return on invested capital, with and without goodwill.

M Leverage, Coverage, and LiquidityA snapshot of the company's financial health.

N Financial SummaryA summary of the proforma financial statements found in the extended report.

VBI Score Action10 Top Pick9 We'd Consider Buying

6 to 8 Constructive (add/trim)3 to 6 Less Exciting (add/trim)1 to 2 We'd Consider Selling

UNDERVALUED

FAIRLY VALUED

OVERVALUED

• Revenue Volatility • Margin Volatility • Earnings Volatility • Cash Flow VolatilityThe information and data contained in this report is not represented or warranted to be timely, complete, accurate, or correct. This report is for informational purposes only and should not be considered a solicitation to buy or sell a security. Before acting on any information in this report, you should consider whether the information is suitable for your particular circumstances and, if necessary, seek professional advice. Assumptions, opinions, and estimates are based on our judgment as of the date of the report and are subject to change without notice. Valuentum is not responsible for any errors or omissions or for results obtained from the use of this report. Redistribution is prohibited without written permission. To license Valuentum research, contact us at [email protected].

About Valuentum

@Valuentum, we strive to stand out from the crowd. Mostinvestment research publishers fall into a few camps,whether it be value, growth, income, momentum, chartistor some variant of the aforementioned. We think each inits own right holds merit, but we think the combination ofthese approaches can be even more powerful. After all,stock price movements aren’t just driven by investors ofthe value or growth variety, but by all market participants.Therefore, we look at stocks from a variety of investmentperspectives in order to better understand and identifyideas. We want to provide relevant information.

The core of our process is grounded in rigorous discountedcash flow analysis and incorporates the concept of amargin of safety. We offer a fair value estimate for eachcompany and provide a relative valuation assessment inthe context of a company’s industry and closest peers. Across section of our ValueCreation™ and ValueRisk™ratings provides a financial assessment of a company’sbusiness quality, while our ValueTrend™ rating offersinsight into the trajectory of a firm’s economic profitcreation. The Economic Castle rating measures themagnitude of future economic value generation, and theDividend Cushion ratio assesses the financial capacity of acompany to keep raising its dividend.

Our analysis doesn’t stop there. We also offer a technicalevaluation of the stock as well as other momentumindicators. We not only want to reveal to readers whichfirms may be undervalued, in our view, but we also wantto provide readers with information to help them assessentry and exit points. Most research publishers focus onarriving at a target price or fair value estimate, but mayfall short of providing a technical assessment to bolsterbuy and sell disciplines. We strive to go the distance andprovide readers with answers--not half the story.

An explanation of our approach would not be complete ifwe didn’t describe our ideal stock idea. We’re lookingfor companies that are undervalued--both on a DCF basisand versus peers--have strong growth potential, have asolid track record of creating economic profits forshareholders with reasonable risk, are strong cash flowgenerators, have manageable financial leverage, and arecurrently showing bullish technical and momentumindicators. For dividend growth ideas, we look forcompanies that have both the capacity and willingness tokeep raising the dividend.

Can such stock ideas exist? Subscribe to Valuentum toreceive our best investment ideas and analysis onhundreds of stocks, dividends, ETFs and more.

Historical firm-specific financial data generates our ValueCreation™, ValueRisk™, and ValueTrend™ ratings. The data provides the basis for our financial forecasts. Full annual forecasts of income statement, balance sheet, and cash flow statement items. Firm-specific cost of equity, cost of debt, weighted average cost of capital, and long-term growth and profitability measures estimated.

A complete three-stage free cash flow to the firm valuation model generates an estimate of the firm's equity value per share based on estimated future free cash flows.The volatility of key valuation drivers are estimated and a margin of safety is determined.

The firm's stock price is compared to the suggested margin of safety. If a firm's stock price falls below the lower bound of our estimated fair value range, it receives Valuentum's highest Value Rating.

Financial Forecasts

Financial Statement Analysis

Discounted Cash Flow Valuation

ModelValueRisk™

Rating

Valuentum Value Rating (VVR)

VBI Score Action10 Top Pick9 We'd Consider Buying

6 to 8 Constructive (add/trim)3 to 6 Less Exciting (add/trim)1 to 2 We'd Consider Selling

Methodology for Picking Stocks - Valuentum Buying Index™ (VBI)

@ Valuentum, we like to look at companies from anumber of different perspectives. The Valuentum BuyingIndex (VBI) combines rigorous financial and valuationanalysis with an evaluation of a stock's technicals to derivea rating between 1 and 10 for each company. The VBIplaces considerable emphasis on a company's discountedcash-flow (DCF) valuation, its relative valuation versuspeers (both forward PE and PEG ratios), and its technicalsin order to help readers assess entry and exit points on themost interesting ideas.

Let's follow the red line on the flow chart below to seehow a company can score a 10, the best mark on the index(a "Top Pick"). First, the company would need to be'undervalued' on a DCF basis and 'attractive' on a relativevalue basis. The stock would also have to be exhibiting

'bullish' technicals. The firm would need aValueCreation™ rating of 'good' or 'excellent', exhibit'high' or 'aggressive' growth prospects, and generate atleast a 'medium' or 'neutral' assessment for cash flowgeneration, financial leverage, and relative price strength.

This is a tall order for any company. Stocks that don'tmake the cut for a 10 are ranked accordingly, with theleast attractive stocks, in our opinion, garnering a ratingof 1 ("We'd sell"). Most of our coverage universeregisters ratings between 3 and 7, but at any given timethere could be large number of companies garneringeither very high or very low scores, especially at marketlows or tops, respectively.

The Best Ideas Newsletter portfolio puts the VBI intopractice.

The information contained in this report is not represented or warranted to be accurate, correct, complete, or timely. This report is for informational purposes only and should not be considered a solicitation to buy or sell a security. Before acting on any information in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice. Assumptions, opinions, and estimates are based on our judgment as of the date of the report and are subject to change without notice. Valuentum is not responsible for any errors or omissions or for results obtained from the use of this report. Redistribution is prohibited without written permission. To license Valuentum research, contact us at [email protected].

DCF FairlyValued

DCF Undervalued

Relative ValueUnattractive/Neutral

Relative Value Attractive

Relative ValueUnattractive/Neutral


Technicals Bearish: 1

Technicals Neutral: 2

TechnicalsBullish: 4

Technicals Bullish: 7

TechnicalsBearish: 6

Technicals >= BullishValueCreation(TM) >= GoodGrowth >= HighCash Flow Generation >= MediumFinancial Leverage <= MediumRelative Strength >= Neutral

Final Score: 10



TechnicalsBearish: 3

Relative Value Unattractive/Neutral











Initial Index Score

DCF Overvalued

GlossaryEstimated Fair Value. This measure is our opinion of the fair equity value per share ofthe company. If our forecasts prove accurate, which may not always be the case, wemay expect a firm's stock price to converge to this value within the next 3 years.

Investment Style. Valuentum uses its own proprietary stock-classification system.Nano-cap: Less than $50 million; Micro-cap: Between $50 million and $200 million;Small-cap: Between $200 million and $2 billion; Mid-cap: Between $2 billion and$10 billion; Large-cap: Between $10 billion and $200 billion; Mega-cap: Over $200billion. Blend: Firm's that we think are undervalued and exhibit high growthprospects (growth in excess of three times the rate of assumed inflation). Value:Firm's that we believe are undervalued, but do not exhibit high growth prospects.Growth: Firms that are not undervalued, in our opinion, but exhibit high growthprospects. Core: Firms that are neither undervalued nor exhibit high growthprospects.

Fair Value Range. The fair value range represents an upper bound and lower bound,between which we would consider the firm to be fairly valued. The range considers ourestimate of the firm's fair value and the margin of safety suggested by the volatility ofkey valuation drivers, including revenue, gross margin, earnings before interest, andenterprise free cash flow (the determinants behind our ValueRisk™ rating).

DCF Valuation. We opine on the firm's valuation based on our DCF process. Firmsthat are trading with an appropriate discount to our fair value estimate receive anUNDERVALUED rating. Firms that are trading within our fair value range receive aFAIRLY VALUED rating, while firms that are trading above the upper bound of ourfair value range receive an OVERVALUED rating.

Company Vitals. In this section, we list key financial information and the sector andindustry that Valuentum assigns to the stock. The P/E-Growth (5-yr), or PEG ratio,divides the current share price by last year's earnings (EPS) and then divides thatquotient by our estimate of the firm's 5-year EPS growth rate. The estimatednormalized diluted EPS and estimated normalized EBITDA represent the five-yearforward average of these measures used in our discounted cash flow model. The P/Eon estimated normalized EPS divides the current share price by estimated normalizeddiluted EPS. The EV/estimated normalized EBITDA considers the current enterprisevalue of the company and divides it by estimated normalized EBITDA. EV is definedas the firm's market capitalization plus total debt, minority interest, preferred stockless cash and cash equivalents.

Relative Value. We compare the firm's forward price-to earnings (PE) ratio and itsprice/earnings-to-growth (PEG) ratio to that of its peers. If both measures fall below thepeer median, the firm receives an ATTRACTIVE rating. If both are above the peermedian, the firm receives an UNATTRACTIVE rating. Any other combination resultsin a NEUTRAL rating.

ValueCreation™. This is a proprietary Valuentum measure. ValueCreation™indicates the firm's historical track record in creating economic value for shareholders,taking the average difference between ROIC (without goodwill) and the firm'sestimated WACC during the past three years. The firm's performance is measured alongthe scale of EXCELLENT, GOOD, POOR, and VERY POOR. Those firms withEXCELLENT ratings have a demonstrated track record of creating economic value,while those that register a VERY POOR mark have been destroying economic value.

Business Quality Matrix. We compare the firm's ValueCreation™ and ValueRisk™ratings. The box is an easy way for investors to quickly assess the business quality ofa company. Firms that generate economic profits with little operating variabilityscore near the top right of the matrix.

Timeliness Matrix. We compare the company's recent stock performance relative tothe market benchmark with our assessment of its valuation. Firms that areexperiencing near-term stock price outperformance and are undervalued by ourestimate may represent timely buys.

The information contained in this report is not represented or warranted to be accurate, correct, complete, or timely. This report is for informational purposes only and should not be considered a solicitation to buy or sell a security. Before acting on any information in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice. Assumptions, opinions, and estimates are based on our judgment as of the date of the report and are subject to change without notice. Valuentum is not responsible for any errors or omissions or for results obtained from the use of this report. Redistribution is prohibited without written permission. To license Valuentum research, contact us at [email protected].

ValueRisk™. This is a proprietary Valuentum measure. ValueRisk™ indicates thehistorical volatility of key valuation drivers, including revenue, gross margin, earningsbefore interest, and enterprise free cash flow. The standard deviation of each measure iscalculated and scaled against last year's measure to arrive at a percentage deviation foreach item. These percentage deviations are weighted equally to arrive at thecorresponding fair value range for each stock, measured in percentage terms. The firm'sperformance is measured along the scale of LOW, MEDIUM, HIGH, and VERY HIGH.The ValueRisk™ rating for each firm also determines the fundamental beta of eachfirm along the following scale: LOW (0.85), MEDIUM (1), HIGH (1.15), VERY HIGH(1.3).

Range of Potential Outcomes. The firm's margin of safety is shown in the graphicof a normal distribution. We consider a firm to be undervalued if its stock price fallsalong the green line and overvalued if the stock price falls along the red line. Weconsider the firm to be fairly valued if its stock price falls along the yellow line.

Return on Invested Capital. At Valuentum, we place considerable emphasis onreturn on invested capital (both with and without goodwill). The measure focuses onthe return (earnings) the company is generating on its operating assets and is superiorto return on equity and return on assets, which can be skewed by a firm's leverage orexcess cash balance, respectively. ValueTrend™. This is a proprietary Valuentum measure. ValueTrend™ indicates the

trajectory of the firm's return on invested capital (ROIC). Firms that earned an ROIClast year that was greater than the 3-year average of the measure earn a POSITIVErating. Firms that earned an ROIC last year that was less than the 3-year average of themeasure earn a NEGATIVE rating.

Technical Evaluation. We evaluate a firm's near-term and medium-term movingaverages and money flow index (MFI) to assign each firm a rating along thefollowing scale: VERY BULLISH, BULLISH, NEUTRAL, BEARISH, and VERYBEARISH.

Cash Flow Generation. Firms' cash flow generation capacity are measured along thescale of STRONG, MEDIUM, and WEAK. A firm with a 3-year historical free cashflow margin (free cash flow divided by sales) greater than 5% receives a STRONGrating, while firms earning less than 1% of sales as free cash flow receive a WEAKrating.

Stock Price Relative Strength. We assess the perfomance of the company's stockduring the past quarter, 13 weeks, relative to an ETF that mirrors the aggregateperformance of constituents of the stock market. Firms are measured along the scaleof STRONG, NEUTRAL, and WEAK. Companies that have outperformed themarket index by more than 2.5% during this 13-week period receive a STRONGrating, while firms that trailed the market index by more than 2.5% during this 13-week period receive a WEAK rating.

Financial Leverage. Based on the firm's normalized debt-to-EBITDA metric, we rank firms on the following scale: LOW, MEDIUM, and HIGH. Companies with a normalized debt-to-EBITDA ratio below 1.5 receive a LOW score, while those with a measure above 3 receive a HIGH score.

Money Flow Index (MFI). The MFI is a technical indicator that measures buyingand selling pressure based on both price and volume. Traders typically use thismeasure to identify potential reversals with overbought and oversold levels. We use a14-week measure to rank firms along the following scale: EXTREMELYOVERBOUGHT (>90), OVERBOUGHT (80-90), NEUTRAL (20-80), OVERSOLD(10-20), EXTREMELY OVERSOLD (0-10).

Upside/Downside Volume. Heavy volume on up days and lower volume on down days suggests that institutions are heavily participating in a stock's upward advance. We use the trailing 14-week average of upside and downside volume to calculate an informative ratio. We rank each firm's U/D volume ratio along the following scale: BULLISH, IMPROVING, DETERIORATING, and BEARISH.

CLX Rating History Price Fair Value VBI18-Jun-21 $172.98 $202.00 315-Oct-20 $219.54 $198.00 618-Aug-20 $228.17 $181.00 416-Apr-20 $196.49 $146.00 425-Nov-19 $145.25 $124.00 323-May-19 $150.14 $128.00 38-Apr-19 $155.49 $116.00 13-Dec-18 $162.47 $112.00 420-Jul-18 $131.80 $102.00 416-Mar-18 $128.49 $97.00 110-Nov-17 $132.05 $97.00 14-Aug-17 $134.49 $98.00 117-Mar-17 $137.54 $98.00 228-Nov-16 $114.02 $97.00 3

Disclosures, Disclaimers & Additional SourcesTo send us feedback or if you have any questions, please contact us at [email protected]. We're always looking for ways to better serve your investment needs and improve our research.

Copyright (c) 2017 by Valuentum, Inc. All rights reserved.No part of this publication may be reproduced in any form or by any means.The information contained in this report is not represented or warranted to be accurate, correct,complete, or timely. This report is for informational purposes only and should not be considered asolicitation to buy or sell any security. No warranty or guarantee may be created or extended bysales or promotional materials, whether by email or in any other format. The securities or strategiesmentioned herein may not be suitable for all types of investors. The information contained in thisreport does not constitute any advice, especially on the tax consequences of making any particularinvestment decision. This material is not intended for any specific type of investor and does nottake into account an investor's particular investment objectives, financial situation or needs. Thisreport is not intended as a recommendation of the security highlighted or any particular investmentstrategy. Before acting on any information found in this report, readers should consider whethersuch an investment is suitable for their particular circumstances, perform their own due-diligence,and if necessary, seek professional advice. The sources of the data used in this report are believed by Valuentum to be reliable, but the data’saccuracy, completeness or interpretation cannot be guaranteed. Assumptions, opinions, andestimates are based on our judgment as of the date of the report and are subject to change withoutnotice. Valuentum is not responsible for any errors or omissions or for results obtained from the useof this report and accepts no liability for how readers may choose to utilize the content. In no eventshall Valuentum be liable to any party for any direct, indirect, incidental, exemplary, compensatory,punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, withoutlimitation, lost income or lost profits and opportunity costs) in connection with any use of theinformation contained in this document. Investors should consider this report as only a single factorin making their investment decision. Valuentum is not a money manager, is not a registered investment advisor, and does not offerbrokerage or investment banking services. Valuentum has not received any compensation from thecompany or companies highlighted in this report. Valuentum, its employees, independentcontractors and affiliates may have long, short or derivative positions in the securities mentionedherein. Information and data in Valuentum’s valuation models and analysis may not capture allsubjective, qualitative influences such as changes in management, business and political trends, orlegal and regulatory developments. Redistribution is prohibited without written permission. Readersshould be aware that information in this work may have changed between when this work waswritten or created and when it is read. There is risk of substantial loss associated with investing infinancial instruments. Valuentum's company-specific forecasts used in its discounted cash flow model are rules-based.These rules reflect the experience and opinions of Valuentum's analyst team. Historical data used inour valuation model is provided by Xignite and from other publicly available sources includingannual and quarterly regulatory filings. Stock price and volume data is provided by Xignite. Nowarranty is made regarding the accuracy of any data or any opinions. Valuentum's valuation modelis based on sound academic principles, and other forecasts in the model such as inflation and theequity risk premium are based on long-term averages. The Valuentum proprietary automated text-generation system creates text that will vary by company and may often change for the samecompany upon subsequent updates. Valuentum uses its own proprietary stock investment style and industry classification systems. Peercompanies are selected based on the opinions of the Valuentum analyst team. Research reports anddata are updated periodically, though Valuentum assumes no obligation to update its reports,opinions, or data following publication in any form or format. Performance assessment ofValuentum metrics, including the Valuentum Buying Index, is ongoing, and we intend to updateinvestors periodically, though Valuentum assumes no obligation to do so. Not all information isavailable on all companies. There may be a lag before reports and data are updated for stock splitsand stock dividends. Past simulated performance, whether backtested or walk-forward or other, is not a guarantee offuture results. For general information about Valuentum's products and services, please contact usat [email protected] or visit our website at www.valuentum.com.

The High Yield Dividend Newsletter portfolio, the Best Ideas Newsletter portfolio and Dividend Growth Newsletter portfolio are not real money portfolios. Any performance, including that in the Nelson Exclusive publication, is hypothetical and does not represent actual trading. Past performance is not a guarantee of future results.

Valuentum is an investment research publishing company.

Valuentum has not owned and does not own any shares of stocks mentioned on its website or in this report. President of Investment Research Brian Nelson does not own any shares of stocks mentioned on Valuentum's website or in this report. Majority share owner of Valuentum, Elizabeth Nelson, currently has exposure to HON in her retirement account.

If an independent contributor or employee mentions a stock he or she owns, we disclose it in the article/report that mentions the security. Please view individual articles on Valuentum's website for additional disclosures. Contact us to learn more about Valuentum's editorial policies.

Clorox CLX FAIRLY VALUED Buying Index™ 3 Value Rating

Documents

Transcript of Clorox CLX FAIRLY VALUED Buying Index™ 3 Value Rating